Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey.
about
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.DNA repair genes polymorphisms and genetic susceptibility to Philadelphia-negative myeloproliferative neoplasms in a Portuguese population: The role of base excision repair genes polymorphisms.Polycythemia Vera Management and Challenges in the Community Health Setting.From leeches to personalized medicine: evolving concepts in the management of polycythemia vera.Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey.A nationwide population-based cross-sectional survey of health-related quality of life in patients with myeloproliferative neoplasms in Denmark (MPNhealthSurvey): survey design and characteristics of respondents and nonrespondents.Exposure-Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies.Characteristics and treatment of polycythemia vera patients in clinical practice: a multicenter chart review on 1476 individuals in Germany.Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physicians.The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark surveyLong-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses.Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results.Prevalence of Physical Problems Detected by the Distress Thermometer and Problem List in Patients With Myeloproliferative Disorders.Recommendations on the use of ruxolitinib for the treatment of myelofibrosis.Effect of ruxolitinib therapy on the quality-of-life of Japanese patients with myelofibrosis.Novel Therapies for Myelofibrosis.Impact of Myeloproliferative neoplasms on patients' employment status and work productivity in the United States: results from the living with MPNs survey.Are patients with high-risk polycythemia vera receiving cytoreductive medications? A retrospective analysis of real-world data.A discussion of blood cancers and the MPN landmark survey
P2860
Q33439559-A6A329DA-E734-49D8-9C68-0035850BB12CQ33751024-90822738-5AD1-429B-AE40-D52B135E6751Q33803036-7E3B2E77-6393-4608-B302-4FE8289700CAQ37555790-C1BF813E-5CE9-4383-9F23-5B521D32E88AQ37631854-99B3304D-76B7-4FC9-888A-3A8E35F772DFQ37682689-8A5BDB8A-60E5-429D-8BA0-BB19E1756D26Q38656601-583564A7-74E6-4473-BC8D-0282CDC3FF8BQ38840350-DF21A7ED-230D-47A7-A156-A1BAF8F2B44BQ39661740-1832EE3A-4EE6-45E8-B942-B18369C565CCQ41508203-AB30098C-95B7-4A05-9A77-7A432DB70F2EQ42228586-060E3086-99F8-4D97-A21D-AD6BC55F68C9Q42702330-1368B62E-A2EC-48AF-91B9-D4AAB44FE0CEQ47655256-A06CF1BC-46DC-48CC-92F7-04F210010D9DQ47815810-422F5E0E-FEAA-494B-9C73-D428B7863829Q49968459-E02FB85F-D98E-441E-8022-D2236225BA48Q52817185-1778EECA-7EC4-4432-A357-77EEF0B100EDQ55278865-D2D1AD46-351A-4FEE-A8C6-3C4873EB2B55Q55651976-86FA9AC9-2A55-47F0-BD8D-830C3DC37C29Q57301968-99B068A5-9C1C-4121-BC4E-D65C6ECCF982
P2860
Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Myeloproliferative neoplasms ( ...... vity: the MPN Landmark survey.
@ast
Myeloproliferative neoplasms ( ...... vity: the MPN Landmark survey.
@en
type
label
Myeloproliferative neoplasms ( ...... vity: the MPN Landmark survey.
@ast
Myeloproliferative neoplasms ( ...... vity: the MPN Landmark survey.
@en
prefLabel
Myeloproliferative neoplasms ( ...... vity: the MPN Landmark survey.
@ast
Myeloproliferative neoplasms ( ...... vity: the MPN Landmark survey.
@en
P2093
P2860
P1433
P1476
Myeloproliferative neoplasms ( ...... vity: the MPN Landmark survey.
@en
P2093
Carole B Miller
David G Dubinski
Dilan C Paranagama
James Mangan
John Boyle
John O Mascarenhas
Maureen Thyne
Ruben Mesa
Salman Fazal
Sara Goldberger
P2860
P2888
P356
10.1186/S12885-016-2208-2
P407
P577
2016-02-27T00:00:00Z
P6179
1003928670